Published on 09/12/2025

Sampling Plans for RTRT: Surrogates vs Direct CQAs

This comprehensive guide aims to provide pharmaceutical professionals with an in-depth understanding of sampling plans for real-time release testing (RTRT), focusing particularly on surrogate measures versus direct quality attributes (CQAs). Drawing upon regulatory guidance and best practices from the US FDA, EMA, and MHRA, this tutorial serves as an essential resource for Quality Assurance, Quality Control, and Regulatory Affairs professionals engaged in continuous manufacturing and process analytical technology (PAT).

Understanding Real-Time Release Testing (RTRT)

Real-time release testing represents a paradigm shift in pharmaceutical quality assurance, emphasizing the need for timely data collection and analysis within the manufacturing process. RTRT allows for the immediate release of product batches based on real-time data rather than solely relying on traditional end-product testing methodologies. The definition of RTRT includes various analytical techniques and the integration of process analytical technology to ensure that the product meets its predefined specifications before its release.

The implementation of RTRT is governed by several regulatory frameworks, including 21 CFR Part 11 in the United States and Annex 11 in Europe, both of which outline the expectations for electronic records and signatures that must be adhered to when using computerized systems for the validation of RTRT procedures.

Furthermore, RTRT is revolutionized by the advancement in multivariate model validation, which uses statistical methods and software tools to analyze multiple variables influencing the manufacturing process. This multifaceted approach not only enhances product quality but also significantly reduces lead times and waste, supporting the principles of Lean Manufacturing.

Developing Sampling Plans for RTRT

The design of a sampling plan is pivotal for effective real-time release testing. Sampling plans serve as a structured framework for determining the quality of products based on select data points within predetermined criteria. The goal of creating a sampling plan is to ensure that sufficient data is captured to make assured decisions about product quality. When developing a sampling plan for RTRT, the following steps should be considered:

Step 1: Define Quality Attributes

• Identify Critical Quality Attributes (CQAs): Establish a comprehensive list of CQAs that are essential for product quality, safety, and efficacy.
• Prioritize CQAs: Using ICH Q9 risk management principles, rank CQAs based on their impact on the product.

Step 2: Select Assessment Techniques

• Surrogate Measures: Evaluate whether surrogate measurements can effectively predict direct CQAs. Surrogate measures may include inline monitoring of critical process parameters (CPPs) that correlate with CQAs.
• Direct Measurements: Assess the capability of direct CQAs to provide an unequivocal measure of product quality. Use validated methods to conduct these assessments accurately.

Step 3: Establish Sampling Frequency

• Continuous Monitoring: In continuous manufacturing, determine whether continuous data gathering is feasible for certain parameters.
• Batch-specific Sampling: For traditional batch processes, specify sampling timings based on critical phases of the manufacturing process.

Step 4: Conduct Risk Assessment

Perform a rigorous risk assessment as per ICH Q9 principles to identify potential failures in both surrogate and direct CQAs. Document the likelihood and severity of risks associated with each CQA and create contingency plans to alleviate these risks, should they arise.

Step 5: Review and Adjust Sampling Strategies

The developed sampling plan must be continuously reviewed and adjusted based on data-derived insights from RTRT. Conduct periodic reviews to determine the efficacy of the sampling strategy, ensuring that it maintains alignment with regulatory standards and business objectives.

Defending Your Sampling Plans During Regulatory Inspections

When presenting your RTRT sampling plans to regulatory bodies such as the FDA or EMA, it is critical to provide thorough justification for both surrogate and direct CQA measurements. This includes showcasing data analytics to support your decisions and demonstrating adherence to regulatory guidelines such as those outlined in the FDA process validation guidance and EU GMP Annex 15. Consider the following points in preparing defense documentation:

Documentation and Transparency

• Maintain Comprehensive Records: Ensure that all decisions made in the sampling plan, including rationales for using surrogates or direct CQAs, are documented systematically.
• Provide Data Visualizations: Utilize graphs and charts to communicate findings effectively, emphasizing trends that support your choice of sampling techniques.

Engage in Collaborative Review

Involve key stakeholders, including process engineers, QA personnel, and regulatory affairs experts, in the sampling plan development process. This multidisciplinary approach ensures that various perspectives are considered, thereby enhancing the credibility of the sampling strategy.

Adequate Training and Communication

Educate team members about the significance of RTRT and the role of specific sampling methods. Clear communication fosters a unified understanding of the sampling plan and the rationale behind surrogate versus quantitative measurements, which is particularly vital for audits and inspections.

Case Studies on Surrogates and Direct CQAs in RTRT

Observing real-world applications of sampling plans can provide valuable insights into their practical execution and the decisions made by others in the industry. These case studies will illustrate the utilization of surrogate versus direct CQAs in RTRT.

Case Study 1: Implementing Surrogate Measures in Continuous Process

This case study describes how a biopharmaceutical company transitioned from traditional batch testing to a continuous manufacturing model utilizing PAT tools. They implemented real-time monitoring of product attributes through surrogate measurements—specifically, turbidity and pH levels. The data indicated strong correlations with potency and impurities, allowing immediate decision-making on product release.

Case Study 2: Utilizing Direct CQAs in a Hybrid Model

The second case reflects a gene therapy company that opted for a combination of both surrogate and direct CQAs in a hybrid manufacturing model. Here, the critical quality attributes included viral titer and DNA integrity, directly measured at specific intervals during the process. The combination allowed for ongoing quality assurance without compromising product safety.

Future Trends in Real-Time Release Testing

The evolution of real-time release testing continues to reshape the pharmaceutical landscape, with rising trends expected to impact its implementation significantly. The following aspects warrant attention:

Enhanced Integration of Artificial Intelligence

Artificial Intelligence (AI) and Machine Learning technologies are expected to assume a larger role in data analytics for RTRT. These technologies enable more efficient data processing, pattern recognition, and predictive analytics that may enhance the reliability of surrogate measures.

Advancements in Process Analytical Technology

Advancements in PAT methodologies are anticipated to reduce variability and increase the precision of inline measurements. Enhanced sensor technologies will support tighter controls over critical parameters, further ensuring product quality in real-time.

Regulatory Evolution and Guidance Updates

Ongoing developments within regulatory bodies such as the FDA, EMA, and MHRA suggest a likelihood of expanded guidance on the application of RTRT methodologies. Staying informed of these developments, potentially through workshops or industry forums, will be crucial for compliance and best practices adherence.

Conclusion

In conclusion, a well-structured sampling plan for RTRT is essential for ensuring the efficacy and safety of pharmaceutical products throughout the continuous manufacturing process. By understanding the distinct roles of surrogate and direct CQAs, pharmaceutical professionals can better safeguard product quality and enhance operational efficiency. The ongoing evolution of regulatory guidance and technological advancements will continue to shape RTRT methodologies, necessitating continuous learning and adoption of best practices.

This guide serves as a foundational resource for industry professionals aiming to navigate the complexities of real-time release testing while remaining compliant with both US and EU regulatory requirements.